Spanish Oncology Genito-Urinary Group   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Madrid Spain (1998)

Organization Overview

First Clinical Trial
2001
NCT00022191
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Spanish Oncology Genito-Urinary Group

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenocortical Carcinoma (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 3)

Disease Progression (Phase 2)

Hypersensitivity (Phase 3)

Kidney Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 3)

Ureteral Neoplasms (Phase 3)

Urethral Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 20